← Product Code [DQK](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DQK) · K181502 # Zio AT ECG Monitoring System, ZEUS System (K181502) _iRhythm Technologies, Inc. · DQK · Aug 29, 2018 · Cardiovascular · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DQK/K181502 ## Device Facts - **Applicant:** iRhythm Technologies, Inc. - **Product Code:** [DQK](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DQK.md) - **Decision Date:** Aug 29, 2018 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 870.1425 - **Device Class:** Class 2 - **Review Panel:** Cardiovascular - **Attributes:** AI/ML, Software as a Medical Device ## Indications for Use The device is intended to capture, analyze and report symptomatic and asymptomatic cardiac events and continuous electrocardiogram information for long-term monitoring. While continuously recording patient ECG, both patient-triggered and automatically-detected arrhythmia events are transmitted to a monitoring center for reporting. After wear, a final report is generated based on the beat-to-beat information from the entire ECG recording. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, lightheadedness, pre-syncope, syncope, fatigue, or anxiety and patients who are asymptomatic. The reports are provided for review by the intended user to render a diagnosis based on clinical judgment and experience. It is not intended for use on critical care patients. ## Device Story ZEUS System is an ECG analysis and reporting software component of the Zio AT ECG Monitoring System. It processes single-lead ECG data recorded by the Zio AT Patch. The system downloads, stores, and analyzes ECG data to generate reports for review by certified cardiographic technicians and clinicians. The core modification involves updating the rhythm classification algorithm from a rule/machine-learning implementation to a deep-learning (ECGDL) basis, integrated with the existing machine-learning (ECGML) implementation. The system identifies various arrhythmias, including atrial fibrillation, heart blocks, pauses, and tachycardias. The output is a clinical report used by healthcare providers to render diagnoses based on clinical judgment. The device benefits patients by providing long-term, continuous cardiac monitoring to detect transient symptoms, facilitating timely clinical decision-making. ## Clinical Evidence Bench testing only. The modified ZEUS System was evaluated in accordance with AAMI ANSI EC57:2012 (Testing and Reporting Performance Results of Cardiac Rhythm and ST-Segment Measurement Algorithms) and IEC 60601-2-47:2012 (Particular requirements for the basic safety and essential performance of ambulatory electrocardiographic systems). Verification and system-level regression testing confirmed the device meets all design specifications. ## Technological Characteristics Software-based ECG analysis system. Utilizes a deep-learning (ECGDL) and machine-learning (ECGML) rhythm classification algorithm. Operates on a PC/Server platform. Complies with AAMI ANSI EC57:2012 and IEC 60601-2-47:2012 standards. Integrated analysis tool architecture. ## Regulatory Identification A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs. ## Predicate Devices - Zio AT ECG Monitoring System ([K163512](/device/K163512.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logos of the Department of Health and Human Services and the Food and Drug Administration (FDA). The Department of Health and Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text. August 29, 2018 iRhythm Technologies, Inc. Rich Laguna Director of Quality and Regulatory Affairs 650 Townsend Street, Suite 500 San Francisco, California 94103 Re: K181502 Trade/Device Name: Zio AT ECG Monitoring System Regulation Number: 21 CFR 870.2800 Regulation Name: Medical Magnetic Tape Recorder Regulatory Class: Class II Product Code: DSH, DOK, DSI, DXH Dated: June 5, 2018 Received: June 7, 2018 Dear Rich Laguna: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part {1}------------------------------------------------ 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. # Arielle Drummond -S for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ #### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration ### Indications for Use K181502 Device Name Zio AT ECG Monitoring System #### Indications for Use (Describe) 510(k) Number (if known) The device is intended to capture, and report symptomatic and asymptomatic cardiac events and continuous electrocardiogram information for long-term monitoring. While continuously recording patient ECG, both patienttriggered and automatically-detected arthythmia events are transmitted to a monitoring center for reporting. After wear, a final report is generated based on the beat information from the entire ECC recording. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, fatigue, or anxiety and patients who are asymptomatic. The reports are provided for review by the intended user to render a diagnosis based on clinical judgment and experience. It is not intended for use on critical care patients. X Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." EF {3}------------------------------------------------ ## SECTION 5. 510(k) Summary ## 1. GENERAL INFORMATION #### 510(k) Sponsor iRhythm Technologies, Inc. 650 Townsend Street, Suite 500 San Francisco, CA. 94103 #### Correspondence Person Rich Laguna Director of Quality and Regulatory Affairs #### Contact Information Email: rlaguna@irhythmtech.com Phone: (415) 632-5749 Date Prepared 08/29/2018 #### 2. PROPOSED DEVICE #### Proprietary Name Zio® AT ECG Monitoring System #### Common Name Zio® AT ECG Monitoring System #### Classification Name Medical magnetic tape recorder [21 CFR§870.2800] Programmable diagnostic computer [21CFR8870.1425] Telephone electrocardiograph transmitter and receiver [21CFR§870.2920] Arrhythmia detector and alarm (including ST-segment measurement and alarm) [21 CFR§870.1025] #### Regulatory Class Class II #### Product Codes DSH, Recorder, Magnetic Tape, Medical DQK, Computer, Diagnostic, Programmable DXH, Transmitters And Receivers, Electrocardiograph, Telephone DSI, Detector And Alarm, Arrhythmia {4}------------------------------------------------ ## 3. PREDICATE DEVICE (ORIGINALLY CLEARED DEVICE) iRhythm Technologies, Inc. Zio AT ECG Monitoring System (K163512) ### 4. DEVICE DESCRIPTION The ZEUS System was most recently 510(k) cleared under K163512 as part of the Zio AT ECG Monitoring System ("Zio" AT"). The original cleared ECG monitoring system components consisted of the 1) Zio AT Patch Recorder Device 2) Zio AT Wireless Gateway Device with Bluetooth and Cellular Technology, and 3) ZEUS System for analysis and reporting. This submission discusses the changes made to the ZEUS System only. The ZEUS System is an electrocardiogram (ECG) analysis and reporting software system, designed to process continuously recorded, signal-lead ECG data. The ZEUS System downloads, stores, analyzes and sorts the ECG data to allow iRhythm's Certified Cardiographic Technicians (CCTs) to generate and distribute a report of the findings contained within the data, thereby enabling the provision of a complete ECG processing and analysis service. The ZEUS System is considered modified as a result of updating its rhythm classification algorithm from a rule and machine-learning implementation to a deep-learning basis. The comparison to the originally cleared device and performance test results demonstrate that the modified ZEUS System is substantially equivalent to the original ZEUS System cleared under K163512, and that the intended use of the device can be consistently fulfilled as originally cleared. #### 5. INDICATIONS FOR USE The device is intended to capture, analyze and report symptomatic and asymptomatic cardiac events and continuous electrocardiogram information for long-term monitoring. While continuously recording patient ECG, both patient-triggered and automatically-detected arrhythmia events are transmitted to a monitoring center for reporting. After wear, a final report is generated based on the beat-to-beat information from the entire ECG recording. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, lightheadedness, pre-syncope, syncope, fatigue, or anxiety and patients who are asymptomatic. The reports are provided for review by the intended user to render a diagnosis based on clinical judgment and experience. It is not intended for use on critical care patients. {5}------------------------------------------------ #### 6. SUBSTANTIAL EQUIVALENCE SUMMARY The indications for use statement for the modified ZEUS System is an identical reflection of the indications for use as represented in the originally cleared device. The performance testing results demonstrate that the differences in the technological characteristics between the devices do not raise new issues of safety or effectiveness. Therefore, the modified ZEUS System is determined to be substantially equivalent to the original ZEUS System device. A comparison table outlining the differences and similarities between the modified and original ZEUS System is provided in Table 5.1. | Feature/
Function | Original Device:
Zio AT ECG Monitoring
System (K163512) | Modified Device:
ZEUS System | | |-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--| | General Characteristics | | | | | Classification | Class II | Class II | | | Classification Regulation(s) | 21 CFR 870.2800
21 CFR 870.1425
21 CFR 870.2920
21 CFR 870.1025 | 21 CFR 870.2800
21 CFR 870.1425
21 CFR 870.2920
21 CFR 870.1025 | | | Product Code | DSH, DQK, DXH, DSI | DSH, DQK, DXH, DSI | | | Patient Environment | Ambulatory | Ambulatory | | | Patient Population | Non-pediatric, non-critical
care patients | Non-pediatric, non-critical care
patients | | | Technological Characteristics | | | | | Data Input | Digital long-term continuous
and transmission ECG | Digital long-term continuous
and transmission ECG | | | Data Download | Yes | Yes | | | Data Storage | Yes | Yes | | | ECG Analysis | Beat
Runs
Rhythm Types
Heart Rates | Beat
Runs
Rhythm Types
Heart Rates | | | Rhythm Detection Algorithm | ECGML | ECGML and ECGDL | | | Feature/
Function | Original Device:
Zio AT ECG Monitoring
System (K163512) | Modified Device:
ZEUS System | | | Rhythm Types | - Atrial fibrillation
- Complete heart block
- Second degree AV
block-type II
- Pause >3 seconds
- Sinus rhythm
- Supraventricular
tachycardia
- Ventricular bigeminy
- Ventricular fibrillation
- Ventricular tachycardia
- Ventricular trigeminy | - Atrial fibrillation
- Complete heart block
- Second degree AV block-
type II
- Pause >3 seconds
- Sinus rhythm
- Supraventricular tachycardia
- Ventricular bigeminy
- Ventricular fibrillation
- Ventricular
tachycardia
- Ventricular trigeminy
- Second degree AV block-
type I
- Ectopic atrial rhythm
- Junctional rhythm
| | | Result Integrator | Algorithm Controller | Algorithm Controller, updated to
initiate ECG Analysis through
ECGDL, and integrate the
ECGML and ECGDL labels | | | Architecture | Integrated Analysis Tool | Integrated Analysis Tool | | | Platform | PC / Server Mix to
Clinician & Patient
Websites | PC / Server Mix to Clinician &
Patient Websites | | | QA Tool | Yes | Yes, updated to support the
expanded rhythms | | | Report Output | Yes | Yes | | | ZEUS Web Services | Store and retrieve the
integrated ECGML Labels
to ZEUS Database | Store and retrieve the integrated
ECGML and ECGDL Labels to
ZEUS Database | | #### Table 5.1: Substantial Equivalence Summary Table {6}------------------------------------------------ Image /page/6/Picture/1 description: The image shows the logo for iRhythm. The logo is in a sans-serif font, with the "i" in black and the rest of the word in blue. There is a trademark symbol to the right of the word. {7}------------------------------------------------ #### 7. PERFORMANCE DATA Safety and performance of the modified ZEUS System has been evaluated and verified in accordance with design specifications and applicable performance standards. The modified device's arrhythmia algorithm detection was tested in accordance to AAMI ANSI EC57: 2012, Testing and Reporting Performance Results of Cardiac Rhythm and ST-Segment Measurement Algorithms; it was also evaluated according to 60601-2-47:2012, Medical Electrical Equipment- Part 2-47: Particular requirements for the basic safety and essential performance of ambulatory electrocardiographic systems. Additionally, the information presented in this submission has been developed in consideration of the recommendations contained in FDA Guidance documents, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" and "Content of Premarket Submission for Management of Cybersecurity in Medical Devices". The nonclinical verification and performance test results established that the device meets its design requirements and intended use, that the modifications to the originally cleared device do not raise new questions of safety and efficacy. During the development, potential hazards were evaluated and controlled by the risk management activities, including risk analysis, risk mitigation, verification and risk-benefit analysis. The verification and full system-level regression testing demonstrate that the device meets all its specifications. #### 8. CONCLUSION Based on the information submitted in this premarket notification, and based on the indications for use, technological characteristics and performance testing comparison to the originally cleared device, the modified ZEUS System raises no new questions of safety and effectiveness and is substantially equivalent to the predicate device. --- **Source:** [https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DQK/K181502](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/DQK/K181502) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com